-- Biopharmaceutical company Biocon (NSE:BIOCON, BOM:532523) has received a notice of compliance from Health Canada for Bosaya (denosumab) and Vezuo (denosumab), according to a Tuesday filing to the Indian stock exchanges.
Bosaya is a biosimilar to Prolia and is most commonly presented as a 60 mg/mL injection for subcutaneous use in a prefilled syringe. Meanwhile, Vezuo, a biosimilar to Xgeva, is mostly presented as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial.
Denosumab products help improve bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.
The company's shares were up nearly 1% in recent trade.